Summary of CRS and CRSwNP prevalence_
| Study | Population / design | CRS prevalence | CRSwNP proportion in CRS | CRSwNP prevalence | Age-related findings |
|---|---|---|---|---|---|
| Khan et al. [14] | European multi-center (GALEN cohort) | 7–27% (range cited across studies) | ∼20–30% | 1.1–4.3% estimated | Mean age 34.3–46.8 years |
| Starry et al. [15] | German claims database | - | - | 0.58–4% estimated | Average age 57.8–61.74 years (only CRSwNP) |
| Mullol et al. [17] | Spain, cross-sectional | 5–12% | 20% | 0.8% | Mean age 42.8–50.1 years |
| Pfaar et al. [16] | Review (multidisciplinary care) | - | 25–30% | 0.5–4% | Not researched |
| Bhattacharyya et al. [21] | US database study | ∼4.9% | 25–30% | - | Mean age 45.8 years |
| Chen et al. [20] | Systematic review | - | 6.1–31% | 1–2.6% | Greatest prevalence at 60–69 years |
| Hulse et al. [22] | Review | 10.9% | - | 2.7% | Peak incidence 45–65 years |
| Stevens et al. [18] | Review | 1–4% | 25–30% | - | Rare <20 and >80 years (red flags) |
Proposed treatment indications for CRSwNP based on disease severity and clinical profile
| Patient Group | Key Selection Criteria | Recommended Therapy | Monitoring/Biomarkers | References |
|---|---|---|---|---|
| Mild Symptoms |
| Saline irrigation + INCS | Endoscopy every 3–6 months | [3–4, 8–9, 81,82,83] |
| Surgery Candidates |
| ESS + postoperative INCS | CT/endoscopy at 3 months | [6–7, 85–86] |
| Biologics Candidates |
| Biologics | At 16–24 weeks: | [3, 9–10, 74] |